Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Division of Otolaryngology - Head and Neck Surgery, Dalhousie University, Halifax, NS, Canada.
J Otolaryngol Head Neck Surg. 2018 Nov 20;47(1):71. doi: 10.1186/s40463-018-0316-5.
Minimally Invasive Ponto Surgery (MIPS) was recently described to facilitate the placement of percutaneous bone anchored hearing devices. As early adopters of this new procedure, we sought to perform a quality assurance project using our own small prospective cohort to justify this change in practice. We chose to examine device stability and to gauge our patients' perspective of the surgery and their overall satisfaction with the process.
A total of 12 adult patients who underwent MIPS between 2016 and 2017 with a minimum post-operative follow-up of 12 months were included in this study. A prospective MIPS research clinic was used to follow patients, assess the implant site soft tissue status and gather qualitative information through patient interviews and surveys.
The mean (SD) soft tissue status score averages using the IPS Scale were low for inflammation 0.1 (0.1), pain 0.1 (0.1), skin height 0.2 (0.1) and total IPS score 0.4 (0.3) indicating minimal soft tissue changes. Patient experiences with MIPS were overwhelmingly positive in reports through the MIPS modified SSQ-8. All patients reported speedy recoveries and no long-term complications. There were zero device losses.
The series presented in this paper represents the first MIPS cohort with long term follow-up to be published to date in North America. Our findings conclude both device stability and patient satisfaction with no loss of fixtures. Consequently, we have adopted MIPS as our procedure of choice for the placement of all percutaneous BAHDs.
微创耳后入路（MIPS）最近被描述为便于经皮骨锚定听力设备的植入。作为这种新手术的早期采用者，我们试图通过自己的小前瞻性队列进行质量保证项目，以证明这种手术实践的改变是合理的。我们选择检查设备的稳定性，并评估患者对手术的看法以及他们对整个过程的总体满意度。
本研究共纳入 12 例 2016 年至 2017 年间接受 MIPS 治疗的成年患者，术后随访时间至少为 12 个月。采用前瞻性 MIPS 研究诊所对患者进行随访，评估植入部位软组织状况，并通过患者访谈和调查收集定性信息。
使用 IPS 量表评估的平均（SD）软组织状况评分均较低，炎症为 0.1（0.1），疼痛为 0.1（0.1），皮肤高度为 0.2（0.1），总 IPS 评分为 0.4（0.3），表明软组织变化极小。通过 MIPS 修改后的 SSQ-8 报告，患者对 MIPS 的体验绝大多数是积极的。所有患者均报告恢复迅速，无长期并发症。无设备丢失。
本文介绍的系列代表了迄今为止在北美发表的第一个具有长期随访的 MIPS 队列。我们的研究结果表明，设备稳定性和患者满意度均无设备丢失。因此，我们已将 MIPS 作为所有经皮 BAHD 植入术的首选术式。
